Context Therapeutics annual depreciation and amortization
2021
2022
2023
2024
2025
Context Therapeutics Depreciation & Amortization Growth & History (CNTX)
Context Therapeutics's depreciation and amortization was $16,251 for fiscal 2025.
View full Context Therapeutics company overviewContext Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $16,251 | $5,370 | +49.35% |
| 2024 | 2024-12-31 | $10,881 | −$1,163 | −9.66% |
| 2023 | 2023-12-31 | $12,044 | $2,776 | +29.95% |
| 2022 | 2022-12-31 | $9,268 | $9,268 | — |
| 2021 | 2021-12-31 | $0 | — | — |
Context Therapeutics quarterly depreciation and amortization
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $6,647 | $2,582 | +63.52% |
| Q1 2026 | 2026-03-31 | $4,687 | $632 | +15.59% |
| Q4 2025 | 2025-12-31 | $4,065 | — | — |
| Q3 2025 | 2025-09-30 | $4,066 | $1,255 | +44.65% |
| Q2 2025 | 2025-06-30 | $4,065 | $1,497 | +58.29% |
| Q1 2025 | 2025-03-31 | $4,055 | $1,487 | +57.90% |
| Q3 2024 | 2024-09-30 | $2,811 | −$278 | −9.00% |
| Q2 2024 | 2024-06-30 | $2,568 | −$626 | −19.60% |
| Q1 2024 | 2024-03-31 | $2,568 | −$625 | −19.57% |
| Q3 2023 | 2023-09-30 | $3,089 | −$104 | −3.26% |
| Q2 2023 | 2023-06-30 | $3,194 | $313 | +10.86% |
| Q1 2023 | 2023-03-31 | $3,193 | $3,193 | — |
| Q3 2022 | 2022-09-30 | $3,193 | $3,193 | — |
| Q2 2022 | 2022-06-30 | $2,881 | — | — |
| Q1 2022 | 2022-03-31 | $0 | — | — |
| Q3 2021 | 2021-09-30 | $0 | — | — |
Context Therapeutics depreciation and amortization trends
Between the periods ended 2021-12-31 and 2025-12-31, Context Therapeutics's depreciation and amortization increased from $0 to $16,251, a change of $16,251. The latest reported quarter, Q2 2026, shows $6,647.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Context Therapeutics source filings ↗